Patent · US Active

Opioid formulations

US12161640B2 · kind B2 · utility

1Cited by

49References

10Claims

0Family size

Assignee

CAMURUS AB · SE

Inventors

Fredrik Tiberg · Lund, SE
Ian Harwigsson · Lund, SE
Markus Johnsson · Lund, SE

Key dates

Filing date	Nov 2, 2023
Grant date	Dec 10, 2024
Priority date	—
Expiry date	Nov 2, 2043

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A depot precursor formulation comprising: a) a controlled-release matrix; b) at least oxygen containing organic solvent; c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base. Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.